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Case report
A  66-year-old  man  was  treated  for  a  malignant
￿ brous  histiocytoma  of  the  proximal  left  tibia,
without metastases, 16 years previously.
After one course of neoadjuvant chemotherapy with
bleomycin–dactinomycin–cyclophosphamide and two
cycles  of  high-dose  methotrexate, an  above-knee
amputation of the left lower limb was performed.
Postoperatively  the  patient  received  adjuvant
chemotherapy  with CDDP–adriamycin  (doxoru-
bicin)–bleomycin–cyclophosphamide  and  dactino-
mycin.
During one of the chemotherapy administrations,
extravasation of adriamycin occurred in the tissues
around the  basilic vein at  the  left  elbow. No  skin
necrosis occurred. After a period of local erythema
and swelling, a multinodular sclerotic lesion devel-
oped, consisting of four to ￿ ve noduli of 0.5–1 cm
diameter, ￿ xed  to  the  skin  and  underlying biceps
muscle which also became indurated.
The  lesions were situated along  the  basilic vein
from the elbow up to where the adriamycin extrava-
sation had occurred (Fig. 1).
Over a period of 16 years there was no evidence of
tumour recurrence. The  patient  remained in good
health and the nodules at his left elbow did not change
in size or number. The patient consulted this year
because of a fast growing mass above the left elbow at
the extravasation site. One of the nodules had signi￿ -
cantly increased in size over a period of 1 month.
On examination, the mass was 6 cm in diameter,
￿ xed to the underlying biceps muscle and overlying
skin, multinodular and non-tender.
Magnetic resonance imaging showed a tumour of
2 ´ 2.5 ´ 4 cm on the ulnar side of the biceps muscle
with  thickening  of  the  overlying  skin  (Fig. 2).
Computerized tomography  of  chest  and  abdomen
did not show metastases except for a small nodular
lesion at the pleura of the left upper lobe.
A resection of the mass en bloc with the medial head
of the biceps, part of the brachialis muscle, and the
subcutaneous  tissue  and  overlying  skin  was
performed. A split thickness skin graft was used to
cover the defect.
Postoperative  wound  healing  was  somewhat
delayed because of partial loss of the skin graft due
to a hematoma.
Two months after the procedure a new CT scan of
the chest showed a clear increase in volume of the
previously  described  nodule. Even  more  pleural
nodules were seen, which were highly suggestive for
pleural  metastasis. The  patient  was  subsequently
treated  with  four cycles of  ifosfamide  with  partial
response: only the initially described nodule was still
present. Via  a  left  thoracotomy, a  resection of  the
nodule en bloc with the lateral side of ribs 4 and 5 was
done.A second nodule was palpated intraoperatively
and resected with the lateral side of rib 3. Multiple
scars in the left lung, especially in the lingula, were
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nated in a multistep way over many years,out of the chronic in￿ ammatory tissue that developed due to a non-speci￿ c cellular
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later into a high-grade pleomorphic sarcoma.
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DOI: 10.1080/1357714021000066386struction of the lateral chest wall was carried out with
a Vicryl mesh.
Histological examination showed metastases of a
high-grade pleomorphic sarcoma in all of the excised
tissues.
Because of the bad hematological tolerance of the
ifosfamide therapy no further adjuvant therapy was
given.The patient remains in close follow-up.
Histology
The tumour at the left elbow was received fresh. A
resection  specimen  consisted  of  a  multinodular
whitish  and  ￿ rm, well-delineated tumour. A  small
tissue fragment was taken for cytogenetic analysis.
The remaining tissue was processed to paraf￿ n. On
histology, a  keloïdal  scar  replaced the  dermal and
subcutaneous tissue (Fig.3).In the deeper part of the
scar, a pleomorphic mesenchymal tumour was seen,
consisting of plump to spindled tumour cells. The
cellularity varied considerably and the matrix ranged
from myxoid to collagenous. A sprinkling of in￿ am-
matory cells was focally seen. Numerous (a)typical
mitoses were present (Fig. 4) and in the centre of the
lesion, areas  of  tumour  necrosis  were  found.
Immunohistochemistry, using  antibodies  against
desmin, a -smooth  muscle  actin, cytokeratin,
myogenin, and  S100  protein, revealed  a -smooth
muscle actin expression in the majority of tumour
cells, and a rare desmin-positive cell. Based on these
￿ ndings, a  diagnosis  of  high-grade  pleomorphic
sarcoma  with  some  myogenic  differentiation  was
reached.
Karyotype of the tumour
Chromosome metaphases were obtained from 5-day-
old  cultures  of  an  overnight  collagenase  disaggre-
gated specimen of the fresh tumour biopsy, utilising
standard procedures. G-banded chromosomes were
evaluated  and  classi￿ ed  according  to  the
International  System  of  Human  Cytogenetic
Nomenclature (1995). Seven metaphases exhibited
abnormal karyotype: 44–45,
XY, add(1)  (p11), add(4)  (q35), -5, dic(7;15)
(q11;p11), -8, del(11) (p11), -13, add(13) (p11), -
14, -20, +3  r, +1–2  mar  [6]/90, idemx2[1]. The
remaining 13 cells had a normal male karyotype.
Discussion
Many epidemiological factors have been suggested in
the  etiology  of  STS  such  as  irradiation, chemical
carcinogens, genetic  disorders, trauma, immuno-
depression, viruses or even late age at ￿ rst pregnancy
or high body mass index.1–7 Some of these are well
recognised; others  are  only  recognised  in  experi-
mental animal models.
Adriamycin  (doxorubicin  hydrochloride)  is  a
widely used anthracycline antibiotic drug especially
prone to cause severe tissue damage on extravasation.
Accidental extravasation has been estimated to occur
in  0.01–6%  of  all  patients  receiving  chemo-
therapy.8–10
As a topoisomerase II poison, it acts on the so-
called cleavable complex in the catalytic cycle of the
essential nuclear enzyme topoisomerase II, thereby
prolonging the transient stage where the enzyme has
locked the gate DNA molecule with a strand break.
The drug action becomes lethal because of the accu-
mulation of DNA  strand breaks.8 In addition, the
cytotoxic activity of dosorobucin is also related to its
quinone structure, which leads to the formation of
cytotoxic free radical oxygen intermediates.11
The  chronicity  of  doxorubicin  extravasation
injuries and ulcers is felt to be secondary to its effect
on host DNA, resulting in host DNA–doxorubicin
complexes, which are released from dead cells and
captured by living cells via endocytosis, thereby recy-
cling  the  necrosing  process  up  to  5  months  after
extravasation.9,12–14
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Fig. 1. Macroscopic aspect of the multinodular sclerotic lesion
￿ xed to the skin at the elbow region (forearm is to the right).
This appearance remained identical during 16 years after the
extravasation and then suddenly changed.
Fig. 2. Transverse section of MRI image just above the elbow.
The tumour enhances peripherally with central necrosis.Histopathological  evidence, however, of  this
prolonged effect is insuf￿ cient.
Measurements of doxorubicin levels in human skin
28 days after extravasation showed surprisingly high
levels without the presence of any metabolites of dox-
orubicin in the samples. Histopathological analysis
performed on the excised skin showed complete epi-
dermal  and  subcutaneous  necrosis, and  reactive
hyperplasia and ￿ brosis.12
Examination of unstained frozen sections of punch
biopsies taken from a doxorubicin-induced ulcer in a
rabbit model by Luedke et al.showed red ￿ uorescence
in the nuclei of all cellular elements,indicating persis-
tence of doxorubicin in the tissues 24 and 168 h after
the injection.Further histological studies of these dox-
orubicin-induced ulcers showed a necrotic lesion with
a lack of in￿ ammatory response,and a primary vascu-
lar or vasospastic mechanism was suggested.15 This
lack of in￿ ammatory in￿ ltrate could be the main fac-
tor interfering with revascularisation and healing.12
Histological studies of human ulcers 2–3 months
after extravasation showed patent blood vessels at the
edge of the ulceration and dense scarring in the der-
mis. As in the observations of Luedke, in￿ ammatory
cells were relatively sparse.16
Rudolph et al. found a normal myo￿ broblast ultra-
structure in experimental skin lesions, induced by
intradermal doxorubicin injection in rats, suggesting
that the observed lack of wound contraction might be
due to cellular dysfunction related to DNA base bind-
ing, which would interfere with the cell replication
necessary for wound healing.17
In the 1960s, Carter et al. reported on the early
development of injection-site sarcomas in rats.18–20
They studied the histopathological changes occurring
after subcutaneous and intraperitoneal injection of
polymerised  nitroso-rubber  compound18 and  after
intramuscular injection of iron-dextran.19
Three  stages  of  development  were  tentatively
de￿ ned.Tiny foci of abnormal ￿ broblasts associated
with increased amounts of acid mucopolysaccharide
ground substance were seen between the pre-existing
multinucleate giant cells at the injection sites.These
foci enlarged,became progressively cellular and pleo-
morphic, and formed circumscribed nodules in the
second stage.Later these nodules became irregular in
outline, invaded adjacent tissues and became recog-
nisable as neoplasms: mainly spindle cell lesions or
mixed tumours with pleomorphic elements.
More recently Richter et al. studied presarcoma-
tous lesions of experimentally induced sarcomas in
rats.21 A benzopyrene–oil mixture was injected intra-
muscularly in the thighs of rats. Groups of animals
were sacri￿ ced every 10 days. It was found that these
injections produced soft tissue sarcomas in a tripha-
sic,overlapping or co-existing pattern that resembled
non-healing granulation process.
An initial,acute in￿ ammatory reaction was charac-
terised by an in￿ ltration of lymphocytes, monocytes
and macrophages. A second, mesenchymal ￿ broma-
tous phase was characterised by the predominance of
spindle-shaped, focally  atypical  ￿ broblast-like  cells
and collagen. A third, premalignant neovascularisa-
tion phase was characterised by dominant capillary
proliferation that evolved into overt malignant ￿ brous
histiocytoma (MFH) with pleiomorphic histiocyte-
and ￿ broblast-like cells with atypical mitoses.Massive
capillary proliferation preceded the development of
manifest  sarcomas, indicating  angiogenesis  as  a
potential factor in tumour growth.
Kirkpatrick et al.22studied the development of mes-
enchymal malignancies after the implantation of eight
different biomaterials in a rat model.
Animals were under observation for 8 or 24 months
after implantation and were sacri￿ ced for histological
and  immunohistochemical analysis. Depending  on
the implanted biomaterial, 12–35% of the implanta-
tion sites showed development of one or more sarco-
mas.The most frequent tumour was malignant ￿ brous
histiocytoma, followed by pleomorphic sarcoma.The
authors proposed a multistage tumorigenesis hypoth-
esis, analogous  to  the  well-known  adenoma–carci-
noma  sequence. Histopathological  examination  of 
the  capsules  revealed  a  variety  of  morphological
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Fig. 3. H&E stain of the keloid scar tissue in the neighbour-
hood of the sarcoma.
Fig.4. Hematoxylin and eosin stain,showing a cellular tumour,
consisting  of  plump/spindled  tumour  cells. There  is  some 
in￿ ammatory background.Arrows indicate mitotic ￿ gures.other, beginning  with  paucicellular  ￿ brous  tissue
tumour. Later, proliferative  lesions  consisting  of
groups of polygonal and/or spindle cells were seen. In
many cases, foci of proliferation were observed with
marked  cellular  typia  such  as  cellular  and  nuclear
pleomorphism coupled with hyperchromasia and well-
de￿ ned nucleoli.
A few capsules revealed a further stage in the devel-
opment  of  a  sarcoma  and showed a  larger  area  of
markedly atypical cells with an organoid pattern that
could be clearly identi￿ ed as malignant. Certain cases
presented a combination of lesions such as manifested
sarcoma with a preneoplastic lesion.
This model, however, is limited to signals that are
elicited locally.The role of systemic factors in the induc-
tion process remains completely unknown, as does the
differentiation  between  local, chemical  and  physical
characteristics as the predominant pathogenic factor.
Postvaccinal sarcoma in cats has been a well-known
entity in veterinary medicine for many years.Hendrick
et al.studied the occurrence of injection-site sarcomas
in cats after vaccination with a mandatory rabies vac-
cine with aluminium-based adjuvants.23
Fifty-one percent of the tumours reviewed were sur-
rounded, and partially in￿ ltrated by lymphocytes and
macrophages  containing  aluminium and  oxygen  as
shown  by  electron  probe  X-ray  microanalysis. The
authors suggested that the persistence of the in￿ am-
matory and immunological reactions associated with
the presence of aluminium in the injection sites predis-
posed the cat to a disturbance of its ￿ brous connective
tissue repair response, eventually leading to neoplasia
in some of the cases. In favour of this hypothesis was
the fact that few cases were found to be ‘transitional’:
microscopic foci of sarcoma were found in areas of
granulomatous in￿ ltration.
We suggest that the extravasation of doxorubicin in
our patient caused a chronic lesion formed due to the
long persistence of doxorubicin–DNA complexes in
the subcutaneous tissues.
These  persistent  complexes  probably  caused  a 
non-speci￿ c cellular damage at the nuclear level,inter-
fering  with  cell  replication  necessary  for  normal 
healing tissues. As a result, this non-healing chronic
in￿ ammatory  tissue  developed  into  a  preneoplastic
mesenchymal tumour and many years later into a high-
grade pleomorphic sarcoma.
To our knowledge,the case of a STS arising at the site
of extravasation of doxorubicin in humans that we pre-
sent is the only one reported in the literature. It illus-
trates that, as in experimental animal models, chronic
￿ brous in￿ ammatory tissue might predispose to sar-
coma development. Adequate initial treatment of the
extravasation on prophylactic resection of the persis-
tent ￿ brous tissue might have prevented the sarcoma.
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